PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in Japan

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Placebo
Drug: CP-690,550

First Posted Date: 2008-01-29

Last Posted Date: 2013-01-25

Lead Sponsor: Pfizer

Target Recruit Count: 140

Registration Number: NCT00603512

Locations: 🇯🇵
Pfizer Investigational Site, Niigata, Japan

Drug Use Investigation of Somatropin for GHD-ADULTS.

Completed

Conditions: Dwarfism, Growth Hormone Deficiency

Interventions: Drug: Somatropin

First Posted Date: 2008-01-28

Last Posted Date: 2014-02-06

Lead Sponsor: Pfizer

Target Recruit Count: 230

Registration Number: NCT00601419

An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis

Phase 2

Completed

Conditions: Cystitis, Interstitial

Interventions: Drug: PF-04383119
Drug: Placebo

First Posted Date: 2008-01-28

Last Posted Date: 2021-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 65

Registration Number: NCT00601484

Locations: 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
🇺🇸
Connecticut Urological Research at Grove Hill, New Britain, Connecticut, United States
🇺🇸
SD Uro-Research, San Diego, California, United States

and more 30 locations

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

Phase 2

Completed

Conditions: Non-Small-Cell Lung Carcinoma
Adenocarcinoma

Interventions: Drug: Bevacizumab
Drug: AG-013736 (axitinib)
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2008-01-25

Last Posted Date: 2013-11-08

Lead Sponsor: Pfizer

Target Recruit Count: 118

Registration Number: NCT00600821

Locations: 🇬🇧
Pfizer Investigational Site, Surrey, United Kingdom

A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia

Phase 2

Completed

Conditions: Postherpetic Neuralgia

Interventions: Drug: pregabalin/PF-00489791
Drug: Placebo
Drug: pregabalin

First Posted Date: 2008-01-24

Last Posted Date: 2021-08-05

Lead Sponsor: Pfizer

Target Recruit Count: 72

Registration Number: NCT00599638

Locations: 🇺🇸
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
🇺🇸
Arthritis Associates of South Florida, Delray Beach, Florida, United States
🇺🇸
Delray Research Associates, Delray Beach, Florida, United States

and more 36 locations

Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors

Phase 1

Completed

Conditions: Neoplasms
Colorectal Neoplasms

Interventions: Drug: sunitinib + FOLFOX

First Posted Date: 2008-01-24

Last Posted Date: 2015-07-15

Lead Sponsor: Pfizer

Target Recruit Count: 53

Registration Number: NCT00599924

Locations: 🇺🇸
Pfizer Investigational Site, Dallas, Texas, United States

Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

Phase 3

Terminated

Conditions: Carcinoma, Squamous Cell
Carcinoma, Adenosquamous
Carcinoma, Large Cell
Carcinoma, Non-Small-Cell Lung

Interventions: Drug: CP-751,871 (Figitumumab)
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2008-01-17

Last Posted Date: 2014-01-13

Lead Sponsor: Pfizer

Target Recruit Count: 681

Registration Number: NCT00596830

Locations: 🇺🇦
Pfizer Investigational Site, Sumy, Ukraine

A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function

Phase 1

Completed

Conditions: Renal Insufficiency, Chronic

Interventions: Drug: PF-00734200

First Posted Date: 2008-01-17

Last Posted Date: 2017-03-10

Lead Sponsor: Pfizer

Target Recruit Count: 30

Registration Number: NCT00596518

Locations: 🇺🇸
Pfizer Investigational Site, Knoxville, Tennessee, United States

Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking

Phase 4

Completed

Conditions: Smoking Cessation

Interventions: Drug: varenicline tartrate (CP-526, 555-18)
Drug: Placebo

First Posted Date: 2008-01-15

Last Posted Date: 2010-07-20

Lead Sponsor: Pfizer

Target Recruit Count: 593

Registration Number: NCT00594204

Locations: 🇻🇪
Pfizer Investigational Site, Caracas, Venezuela

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer ALK-positive
Systemic Anaplastic Large-Cell Lymphoma
Non-Small Cell Lung Cancer c-Met Dependent
Non-Small Cell Lung Cancer ROS Marker Positive
Advanced Malignancies Except Leukemia

Interventions: Drug: PF-02341066
Drug: Rifampin
Drug: Itraconazole

First Posted Date: 2008-01-03

Last Posted Date: 2023-02-08

Lead Sponsor: Pfizer

Target Recruit Count: 596

Registration Number: NCT00585195

Locations: 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States

and more 25 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy